Videos

Risk-Based Management of Follicular Lymphoma

Risk-Based Management of Follicular Lymphoma

Emil Christensen, PhD candidate, Aarhus University Hospital, Denmark, discusses a liquid biopsy analysis of <em>FGFR3</em> and <em>PIK3CA</em> hotspot mutations for disease surveillance in bladder cancer.

Oddbj&oslash;rn Straume, MD, PhD, associate professor, department of Clinical Science, Haukeland University Hospital, discusses a study investigating BGB324 with pembrolizumab or dabrafenib/trametinib in patients with advanced non-resectable or metastatic melanoma.&nbsp;

Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.

Elizabeth Swisher, MD, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Treatment of Follicular Lymphoma

Treatment of Follicular Lymphoma

Advanced Squamous Non-Small Cell Lung Cancer